Molecular and Genetic Medicine

Gupta and Raghav, J Mol Genet Med 2015, 9:4
http://dx.doi.org/10.4172/1747-0862.1000191

Review Article Open Access

Single Cell Transcriptomics for Autoimmune Disorders

Bhawna Gupta[1*] **and Sunil Kumar Raghav**[2]

[1]*School of Biotechnology, KIIT University, Bhubaneswar, Odisha, India*

[2]*Institute of Life Sciences, Nalco square, Bhubaneswar, Odisha*

***Corresponding author:** B Gupta, School of Biotechnology, KIIT University, Bhubaneswar, Odisha, India, E-mail: raghuvanshi2010@yahoo.co.in

Received date: October 01, 2015; **Accepted date:** November 12, 2015; **Published date:** November 19, 2015

Copyright: © 2015 Gupta B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

The interplay of genetic, immunological and environmental factors is the driving force towards autoimmunity and each of these branches of biological science is necessary to identify the cause and progress of autoimmune disorders. Differential transcript abundance as an effect of environmental or epigenetic modifications may directly regulate emergence while a sustained copy number increase may drive disease progression. A precise evaluation of these transcript level differences could be the key to understand the mechanism of development and progression of autoimmune diseases however it is imperative to quantitate the subtle changes at the highest resolution. This review summarizes the studies that have explored the importance of analyzing differential transcriptome at single cell resolution, further to emphasize the importance of this approach for enhanced understanding and to identify more sensitive and specific biomarkers for autoimmune diseases.

Keywords: Transcriptomics; Autoimmune disease; Erythematosus; Major histocompatibility complex; CD8+ T cells

Description

The human body has invested enough to create a well-armed army for defense against intruders. Two well-organized lines of defense have been built up to an extent that if one fails to completely eliminate the invaders the other insinuates briskly. The interplay of these innate and adaptive immune responses proactively helps to combat diseases [1]. With the introduction of autoimmunity as an immune dysfunction that counters self, results in target tissue destruction and involves multi-organ ramification; an extensive research was initiated to understand the mechanism of immune dysfunction for identification of new therapies to treat and even prevent autoimmune diseases. More than seventy autoimmune disorders including rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus have been registered so far that are known to be a consequence of excessive immune responses. Despite their heterogeneity, autoimmune diseases share epidemiological, etiopathogenic, and clinical features [2,3]. The past two decades of research has yielded rich insights into the pathogenesis and molecular mechanisms responsible for progression of many autoimmune diseases [4-8].

The predictive onset of immunologic changes or the outcome of autoimmune disease is increasingly being employed by measuring serum auto-antibodies. An expanding spectrum of auto-antibodies has been reported for different autoimmune diseases. Besides rheumatoid factors (RF) [9,10] and anti-citrullinated peptide (anti-CCP [10]) as predictors of rheumatoid arthritis (RA), we proposed the diagnostic capacity of anti-Mannose binding lectin (anti-MBL) auto-antibodies for RA [11]. Elevated titres of anti-nuclear antibodies (ANA) are seen in patients with systemic autoimmune rheumatic diseases [12]; anti-MDA5 antibodies in myositis [13,14] and auto-antibodies to 3-hydroxy-3- methylglutaryl-coenzyme-A reductase (HMGCR) in patients with immune mediated necrotizing myopathies [15] are well recognized. The thrombotic events in anti-phospholipid syndrome are mediated by anti-phospholipid antibodies such as anti-cardiolipin antibodies (Acl [16]) and/or anti-β2 glycoprotein I (β2GPI [16,17]) and/or lupus anticoagulant (LAC [16]). Considering the fact that autoantibody signatures can often be detected prior to the onset of the disease, they have been constantly used as predictive biomarkers.

Genomics of Autoimmunity

Many studies suggest that a blend of environmental and genetic factors is responsible; both are necessary, but are insufficient alone for full articulation of an autoimmune disease. An altered combination of genetic sequences has been implicated to provide the foundation for a potential autoimmune disorder that can be triggered with an external stimulus following a stochastic event. Studies involving monozygotic twins have facilitated the understanding and have further confirmed the role of genetic factors in establishment of autoimmune disorders. Multiple gene loci have been conferred responsible for a disease outcome moreover shared pathogenesis by a single gene has been shown to be responsible for various autoimmune diseases [18].

Major histocompatibility complex (MHC) presents a predominant region in human genome with association of variants at this locus with predisposition to numerous autoimmune disorders [19]. Human MHC, known as human leukocyte antigen (HLA, class I and class II) are highly polymorphic and provide genetic restriction for T lymphocyte responses. An aberrant class II presentation of self or foreign peptides to autoreactive T lymphocytes has been suggested to play a critical role in disease specific associations [19]. Allelic heterogeneity in HLA-DRB, HLA-DR4 genes plays role in susceptibility to multiple sclerosis [20-26]; while HLA-DQ is the major disease-predisposing locus in Type 1 diabetes with DRB1*04-DQA1*0301-DQB1*0302 and DRB1* 03-DQA1*0501- DQB1*0201 haplotypes predisposing European populations to the disease [27-32]. The shared epitopes coded by HLA-DRB1 alleles is a significant genetic risk factor for rheumatoid arthritis [33]. Also shared HLA haplotypes have been implicated in different diseases highlighting their central role in mediating host inflammatory responses [19]. Others and we

have shown that a myriad of non-HLA genes like PTPN22 [34], TNF [34-36], CTLA-4 [34], MBL2 [37], PADI [34] may be prognostic for autoimmunity. Many genome-wide association studies (GWAS) have highlighted genes and pathways pertinent with autoimmune diseases [18,38] concluding that genomic studies have profound clinical applications. Hence genetic approaches to identify target or druggable genomes have been well explored since past decade [39,40].

Transcriptomics in Autoimmunity: Advantages at Single Cell Resolution

Determining the genetic makeup though can be helpful in predicting disease predisposition and progression however occurrence of geographic and occupational clustering of autoimmune patients [41-43], external factors including exposure to tobacco smoke [44,45], radiation [46,47], chemical compounds [48], epigenetic modifications [49] and infectious agents [50] play significant role in development of autoimmune disease, providing substantial evidences of the environmental involvement in these diseases. The environmental factors, dynamic changes in cellular make up of tissues and infectious challenges substantially influence gene transcription thereby affecting transcript abundance.

Cell to cell variability owing to their stochastic and deterministic nature can only be tapped by following their transcriptional states. Alterations in RNA abundance will reflect a prompt and sustained response against self-antigens as well as processes involving recurring and remitting patterns of the disease. We recently showed that CD^{8+} T cells have profound differences in their tumor activity in melanoma patients depending on the peptide vaccines with either immunodominant HLA-A*0201-restricted native peptide of the melanoma antigen Melan-AMART-126-35 (EAAGIGILTV) or single amino acid substituted analog peptide (A27L; ELAGIGILTV) [51]. This discrepancy arrives due to differential expression of transcriptome for an appropriate effector function. Thus transcriptional activity being oscillatory, adapting swiftly to the needs of environmental and physiological cues provides a powerful tool for logical exploitation to identify biomarkers describing the physiological status of a disease as well as substantiation of therapeutic interventions.

Major technological breakthroughs to study spatio-temporal differences in transcript abundance have provided an apprehensive view of disease predisposition and progression [52]. DNA microarrays have been extensively used for transcriptional profiling of many autoimmune diseases [35,53-69]. Quantitative PCR [70,71], Nanostring [72,73] and more recently next generation sequencing (NGS) technologies [74,75] have helped us to build gene expression patterns and networks for disease associations. Though the technology has advanced drastically from PCR to microarray to NGS analysis, the asymptote of genetic analyses will soon reach if we continue to analyze population of cells.

We surmise in differential transcriptome by observing subtle changes between conditions by analyzing population of cells and accepting implicitly that the constituent cells behave analogously. This averaging over population results in loss of critical information by responding cells over non-responders. Time has come that we understand and treat each cell individually. While sequencing single neuron cDNA libraries from electrophysiologically identified warm sensitive neurons [76], could characterize active adult neurons and detect rarely expressed receptors that were undetectable in population pools. Immune system players like dendritic cells (DC) are not a single cell types but a system of cells that arise from both the myeloid and lymphoid hematopoietic lineages [77]. Various DC subtypes are thought to differ in their capacity to either stimulate or inhibit the immune response [77]. Thus it is extremely important to understand how every cell of a subset responds to external or physiological stimulus, and then look for patterns in the behavior that would tell us how these cells make decisions [78,79] observed extensive bimodality in the transcriptional response of mouse bone-marrow-derived dendritic cells (BMDCs) to lipopolysaccharide by measuring RNA abundance and splicing patterns of individual BMDCs that remained previously undetected. We recently showed that single-cell gene expression profiling allows identification of qualitative differences in CD8+ T-cell responses elicited by different gene-based vaccines in melanoma patients. To this extent we as well observed that within the population of CD8+ T cells with even identical TCR clonotypes, individuals developed differential effector function depending on their gene expression pattern [51]. Moreover, analyzing CD8+ T cells at the single cell level revealed cellular heterogeneity and polyfunctionality within tumor- and virus-specific CD8+ T cell sub-populations which was previously undetected using a population of cells, demonstrating the power and promise of single-cell transcriptomics in uncovering functional diversity between cells and in deciphering cell states. Ramskold et al., [66] identified distinct gene expression patterns as well as candidate biomarkers for melanoma circulating tumor cells using single cell enabled mRNA sequencing. Even isogenic cells in culture show strong variability. Continuously changing microenvironment for individual cells in cell culture conditions has been demonstrated to propagate changes in cell-cell-matrix dialogue such that each cell assimilates subtle differences [80-83]. Recently Herderschee et al. [84] reviewed the role of single cell technologies in providing an unprecedented detail of immune responses. Moreover in their effort in analyzing in vivo transcriptional states of single cells of complex tissues to characterize cell-type compositions, Jaitin et al. [85] demonstrated the power of single-cell RNA-seq for comprehensive cellular decomposition of complex tissues.

Thus to our belief, synchronization of cells by isolating with identical characteristics followed by an experimental protocol and interpreting data is nothing but a concocted extrapolation. Hence given the inherent stochasticity and heterogeneity of multicellular tissues, single cell transcriptomics is essential to understand the biological functions.

For autoimmune disorders, being inherited but driven by environmental cues, it makes it imperative to view their real time spatio-temporal dynamics at a single cell resolution. The major challenge that needs to be addressed in the studies involving autoimmune disorders is finding predictive biomarkers of the disease. For the purpose, the transcript signatures of individual cells will not only hasten an unbiased discovery of overlooked key molecules mediating robust effects but will also enable identification of circulating rare cell population that may be stimulating neighbor cells for the visible disease outcome. Blood has always been a preferred tissue for gene expression analysis studies to identify potential biomarkers and clues for disease pathogenesis. However blood only provides a snap shot of the intricate immune networks operating in the body. In autoimmune disorders like juvenile rheumatoid arthritis where the cells migrate from the blood and accumulate at the site of inflammation [86,87], sampling the site of inflammation like synovial fluid, tissue cells (biopsy) will provide better and detailed view of specific immune reaction. Again these sites are reservoirs of diverse cell types with lineage abundances shadowing the few deterministic

cells. Understanding the functional relevance of these cells can only be possible following an analysis at single cell level enhancing the sensitivity and specificity of the identified biomarker. Covey et al. [88] clearly highlighted the significance of single cell analysis by network profiling in biological characterization of autoimmune diseases like systemic lupus erythematosus and rheumatoid arthritis benefiting clinical medicine and drug development. Using multiparameter single-cell measurements Candia et al. [89] identified phenotypic differences between healthy and diseased patients, as well as between Behçet's disease and sarcoidosis, the diseases that share many common features and are difficult to diagnose.

Understanding the progression of an autoimmune disorder by identifying classifiers that distinguish different clinical forms or activity phases of the disease is as intriguing as finding diagnostic markers and poses another challenge in the field of research. Finding stringent predictors at distinct stages can be challenging if the analysis masks important information pertaining to population level analysis. It is also important to decipher the processes influencing initial tolerance breakdown and to distinguish them from those responsible for perpetuating autoimmune pathology. Analyzing and averaging over a population of cells that includes many distinct intermediate differentiation states will compromise over absolute results and will alter differentiation kinetics pertinent with the disease progression. This highlights the importance and necessitates the use of transcriptomics in understanding autoimmunity at the single cell resolution.

Further the prognostic competence of the proposed biomarker needs to be validated before compliance and RNAi mediated in vitro protocols are often exploited for the purpose. Snijder et al., [90] while analyzing population context of RNAi screens have confirmed that the cell population averaging can be misleading in interpreting even a perturbation phenotype and the methods that have the depth to measure activities at single-cell resolution can only overcome this issue, further acknowledging the potential of single cell analysis.

Patients with autoimmune disorders like rheumatoid arthritis, psoriasis, and inflammatory bowel disease are prescribed with disease modifying drugs or anti-TNF therapies. Very often the patients undergo remission, however occasionally they show a progressive relapse [91,92]. It will be interesting to follow patterns of gene expression and regulated gene networks during the course of the disease as well as in patients proceeding towards clinical remission.

Moreover understanding the discrete genetic modifications and the consequent signaling mechanisms leading to an occasional relapse as well as determining the efficiency with which the patient responds towards the drug will be of paramount importance. It is thus fundamental to understand the gene expression signatures that will allow us to discriminate between clinical phases of relapse and remission between patients eventually substantiating the efficacy of therapeutic interventions. A well-targeted intervention requires a more complete map of the cellular mechanisms and genes underpinning self-tolerance, thus single cell enabled NGS will be beneficial in this regard to not only discern overlooked transcripts but to also identify distinguished cells.

Moreover clustering together of analyzed single cells according to qualitative and quantitative differences in their transcript expression patterns manipulating the cellular signaling mechanisms will help us answer the key question of why only a subset of cells are responders and not the entire cell population.

Challenges of Single Cell Transcriptomics

Though in relatively naïve stage, single cell transcriptomics will revolutionize our understanding of the functional identity of each cell of a subset (Figure 1). Methods employed to pick up single cells are debatable and are a matter of personal and or practical preference however we believe that the methods should be rapid and at near-physiological conditions. Handpicking of neuronal cells has been demonstrated by Morris et al., [93], we used flowcytometry based sorting of each melanoma antigen specific CD8+ T cell directly in 96 well plates [51,94,95], laser microdissection or micromanipulation [96] and microfluidics for isolation of single cells has been extensively exploited [97-102]. Lengthier protocols to isolate single cells may lead to alterations of gene expression patterns as well as cell death.



Figure 1: Protocol for single cell transcriptomics.

Nonetheless the first question that puzzles is 'how many cells'? Even using as few as ten cells, single cell sequencing studies have demonstrated the potential to distinguish complex heterogeneity [103]. Since most methods employ linear amplification of transcripts for a statistical readout of relative abundance, a better number will definitely provide conclusive results. However, for analyzing rare or low-abundance cells, tag-based sequencing of 5' or 3' e nds provides a scaled up assay for better estimates of transcript counts [80,103-105]. Still the numbers can be enormous. To address the issue, efforts have

been put together by researchers to build cost effective as well as high-throughput methodologies [103-112]. Multiplexing individual cells marked with specific barcodes for NGS work wonders to overcome the cost barriers (Soumillon et al.). NGS though not cheap will no longer remain the most expensive part of the protocol.

Following a well-planned experiment the next step is to generate meaningful data to build disease associated gene networks for effective perturbations necessitate another brainstorming engagement. To begin with, the use of RNA spike-ins [113], incorporating a unique identifier into every molecule prior to amplification [105,114]; direct sequencing of single molecules of RNA from single cells [26,83] can overcome the concept of technical noise in these single cell experiments thereby enabling hand picking of relevant transcripts. Moreover, factors such as heterogeneity of starting populations owing to the cell source, sample collection and processing methods as well as analysis platforms may well contribute to the differences observed between transcriptomic studies. However if each cell is analyzed individually in its particular time and space, there are better chances of reproducible representation of cell population.

Conclusion

Knowing the unique transcript signature of each cell of a subset in its particular time and space will allow us to disclose predisposition potential, predict the vivacity with which the cell can respond to a stimulus and reconstruct cell lineage trees with very high precision. Considering the ease of data collection and interpretation, it is mandatory and increasingly important to collect meaningful information and single cell enabled analysis can only be effective in this regard. It is the method of present and future. However, extending single-cell analyses beyond the transcriptome is indeed an area of interest. Since epigenetics modifications have been implicated in various autoimmune diseases [49] methods pertaining to single cell epigenetics would be of increasing priority to understand transcriptional regulation and build regulatory networks for better perturbation strategies. Fessenden [115] in her article has very evidently summarized that examining epigenetic modifications in single cells will allow researchers to establish the differences among the mosaic of cells as well as the functional consequences of those differences for development and disease states. Besides these protein-gene interactions, it is necessary to identify the cell specific protein-protein interactions to define the discrete protein interactome responsible for pathogenesis and progression of autoimmune disorders [116-119].

References

1. Janeway CA, Travers P Jr, Walport M, Shlomchik MJ (2001) The Immune System in Health and Disease. Immunobiology (5thedn), Garland Science, US.
2. Mak TW, Jett ME, SaundersBradley D (2014) Chapter: Autoimmune Diseases, In Primer to the Immune Response (2ndedn), Academic Cell, Boston, 517-515.
3. Davidson A, Diamond B (2014) Chapter 3 - General Features of Autoimmune Disease, In The Autoimmune Diseases. In: Noel R. RoseIan, R. Mackay (5thedn), Academic Press, Boston.
4. Goodnow CC (2007) Multistep pathogenesis of autoimmune disease. Cell 130: 25-35.
5. Ohashi PS (2002) T-cell signalling and autoimmunity: molecular mechanisms of disease. Nat Rev Immunol 2: 427-438.
6. Albert LJ, Inman RD (1999) Molecular mimicry and autoimmunity. N Engl J Med 341: 2068-2074.
7. Atassi MZ, Casali P (2008) Molecular mechanisms of autoimmunity. Autoimmunity 41: 123-132.
8. Handel AE, Ebers GC, Ramagopalan SV (2010) Epigenetics: molecular mechanisms and implications for disease. Trends Mol Med 16: 7-16.
9. Eggert M, Zettl UK, Neeck G (2010) Autoantibodies in autoimmune diseases. Curr Pharm Des 16: 1634-1643.
10. Rantapää-Dahlqvist S, Jong Ben AWde, Berglin E, Hal lmans G, Wadell G, et al. (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis & Rheumatism 48: 2741-2749.
11. Gupta B, Raghav SK, Agrawal C, Chaturvedi VP, Das RH, et al. (2006) Anti-MBL autoantibodies in patients with rheumatoid arthritis: prevalence and clinical significance. J Autoimmun 27: 125-133.
12. Smeenk RJ (2000) Antinuclear antibodies: cause of disease or caused by disease? Rheumatology (Oxford) 39: 581-584.
13. Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri S, et al. (2012) The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology 51:1278-1284.
14. Casciola-Rosen L, Mammen AL (2012) Myositis autoantibodies. Curr Opin Rheumatol 24: 602-608.
15. Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, et al. (2011) Autoantibodies against 3-hydroy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 63: 713-721.
16. Misita CP, Moll S (2005) Antiphospholipid antibodies. Circulation 112: e39-44.
17. Galli M, Luciani D, Bertolini G, Barbui T (2003) Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 102: 2717-2723.
18. Zenewicz LA, Abraham C, Flavell RA, Cho JH (2010) Unraveling the Genetics of Autoimmunity.Cell 140: 791-797.
19. Fernando MM, Stevens CR, Walsh EC, De Jager PL, Goyette P, et al. (2008) Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet 4: e1000024.
20. Yeo TW, De Jager PL, Gregory SG, Barcellos LF, Walton A, et al. (2007) A second major histocompatibility complex susceptibility locus for multiple sclerosis. Ann Neurol 61: 228-236.
21. de Jong BA, Huizinga TW, Zanelli E, Giphart MJ, Bollen EL, et al. (2002) Evidence for additional genetic risk indicators of relapse-onset MS within the HLA region. Neurology 59: 549-555.
22. Sawcer S, Compston A (2006) Multiple sclerosis: light at the end of the tunnel. Eur J Hum Genet 14: 257-258.
23. Marrosu MG, Murru R, Murru MR, Costa G, Zavattari P, et al. (2001) Dissection of the HLA association with multiple sclerosis in the founder isolated population of Sardinia. Hum Mol Genet 10: 2907-2916.
24. Silva AM, Pereira C, Bettencourt A, Carvalho C, Couto AR, et al. (2007) The role of HLA-DRB1 alleles on susceptibility and outcome of a Portuguese Multiple Sclerosis population. J Neurol Sci 258: 69-74.
25. Saruhan-Direskeneli G, Esin S, Baykan-Kurt B, Ornek I, Vaughan R, et al. (1997) HLA-DR and -DQ associations with multiple sclerosis in Turkey. Hum Immunol 55: 59-65.
26. Aláez C, Corona T, Ruano L, Flores H, Loyola M, et al. (2005) Mediterranean and Amerindian MHC class II alleles are associated with multiple sclerosis in Mexicans. Acta Neurol Scand 112: 317-322.
27. Laroni A, Calabrese M, Perini P, Albergoni MP, Ranzato F, et al. (2006) Multiple sclerosis and autoimmune diseases: epidemiology and HLA-DR association in North-east Italy. J Neurol 253: 636-639.
28. Todd JA (1990) Genetic control of autoimmunity in type 1 diabetes. Immunol Today 11: 122-129.
29. Davies JL, Kawaguchi Y, Bennett ST, Copeman JB, Cordell HJ, et al. (1994) A genome-wide search for human type 1 diabetes susceptibility genes. Nature 371: 130-136.
30. Thorsby E, Rønningen KS (1993) Particular HLA-DQ molecules play a dominant role in determining susceptibility or resistance to type 1 (insulin-dependent) diabetes mellitus. Diabetologia 36: 371-377.
31. Onengut-Gumuscu S, Concannon P (2002) Mapping genes for autoimmunity in humans: type 1 diabetes as a model. Immunol Rev 190: 182-194.
32. She JX (1997) Susceptibility to type I diabetes: HLA-DQ and DR revisited. Immunol Today 17: 323-329.
33. Dorman JS, Bunker CH (2000) HLA-DQ locus of the human leukocyte antigen complex and type 1 diabetes mellitus: a HuGE review. Epidemiol Rev 22: 218-227.
34. Holoshitz J (2010) The rheumatoid arthritis HLA-DRB1 shared epitope. Curr Opin Rheumatol 22: 293-298.
35. Rioux JD, Abbas AK (2005) Paths to understanding the genetic basis of autoimmune disease. Nature 435: 584-589.
36. Raghav SK, Gupta B, Agrawal C, Chaturvedi VP, Das HR (2006) Expression of TNF-alpha and related signaling molecules in the peripheral blood mononuclear cells of rheumatoid arthritis patients. Mediators Inflamm 2006: 12682.

37. Gupta B, Agrawal C, Raghav SK, Das SK, Das RH, et al. (2005) Association of mannose-binding lectin gene (MBL2) polymorphisms with rheumatoid arthritis in an Indian cohort of case-control samples. J Hum Genet 50: 583-591.

38. Agrawal C, Raghav SK, Gupta B, Das RH, Chaturvedi VP, et al. (2005) Tumor necrosis factor-alpha microsatellite polymorphism association with rheumatoid arthritis in Indian patients. Arch Med Res 36: 555-559.

39. Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, et al. (2013) Genome- Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. Plos Genet 9.

40. Lindsay MA (2003) Target discovery. Nat Rev Drug Discov 2: 831-838.

41. Costa PR, Acencio ML, Lemke N (2010) A machine learning approach for genome-wide prediction of morbid and druggable human genes based on systems-level data. BMC Genomics 11 Suppl 5: S9.

42. Javierre BM, Hernando H, Ballestar E (2011) Environmental triggers and epigenetic deregulation in autoimmune disease. Discov Med 12: 535-545.

43. Cooper GS, Bynum ML, Somers EC (2009) Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun 33: 197-207.

44. Youinou P, Pers JO, Gershwin ME, Shoenfeld Y. (2010). Geo-epidemiology and autoimmunity. J. Autoimmun 34: J163-J167.

45. Harel-Meir M, Sherer Y, Shoenfeld Y (2007) Tobacco smoking and autoimmune rheumatic diseases. Nat Clin Pract Rheumatol 3: 707-715.

46. Costenbader KH, Karlson EW (2006) Cigarette smoking and autoimmune disease: what can we learn from epidemiology? Lupus 15: 737-745.

47. Ponsonby AL, McMichael A, van der Mei I (2002) Ultraviolet radiation and autoimmune disease: insights from epidemiological research. Toxicology 181-182: 71-[78].

48. Cooper GS, Miller FW, Germolec DR (2002) Occupational exposures and autoimmune diseases, International. Immunopharmacol 3: 303-313.

49. Powell JJ, Van de Water J, Gershwin ME (1999) Evidence for the role of environmental agents in the initiation or progression of autoimmune conditions. Environ Health Perspect 107 Suppl 5: 667-672.

50. Gupta B, Hawkins RD (2015) Epigenomics of autoimmune diseases. Immunol Cell Biol 93: 271-276.

51. Bach JF (2002) The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347: 911-920.

52. Speiser DE, Wieckowski S, Gupta B, Iancu EM, Baumgaertner P, et al. (2011) Single cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypes. Proc Natl Acad Sci USA 108: 15318-15323.

53. Collares CVA, Donadi EA (2014) Transcriptome Profiling in Autoimmune Diseases. Transcriptomics in Health and Disease, Springer International Publishing, Switzerland.

54. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, et al. (2003) Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 197: 711-723.

55. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, et al. (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 100: 2610-2615.

56. Crow MK, Wohlgemuth J (2003) Microarray analysis of gene expression in lupus. Arthritis Res Ther 5: 279-287.

57. Han GM, Chen SL, Shen N, Ye S, Bao CD, et al. (2003) Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 4: 177-186.

58. Allantaz F, Chaussabel D, Stichweh D, Bennett L, Allman W, et al. (2007) Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med 204: 2131-2144.

59. Ogilvie EM, Khan A, Hubank M, Kellam P, Woo P (2007) Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum 56: 1954-1965.

60. Fall N, Barnes M, Thornton S, Luyrink L, Olson J, et al. (2007) Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum 56: 3793-3804.

61. Barnes MG, Grom AA, Thompson SD, Griffin TA, Pavlidis P, et al. (2009) Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum 60: 2102-2112.

62. Achiron A, Feldman A, Mandel M, Gurevich M (2007) Impaired expression of peripheral blood apoptotic-related gene transcripts in acute multiple sclerosis relapse. Ann N Y Acad Sci 1107: 155-167.

63. Singh MK, Scott TF, LaFramboise WA, Hu FZ, Post JC, et al. (2007) Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy. J Neurol Sci 258: 52-59.

64. Edwards CJ, Feldman JL, Beech J, Shields KM, Stover JA, et al. (2007) Molecular profile of peripheral blood mononuclear cells from patients with rheumatoid arthritis. Mol Med 13: 40-58.

65. van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, et al. (2007) Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 66: 1008-1014.

66. Lequerré T, Gauthier-Jauneau AC, Bansard C, Derambure C, Hiron M, et al. (2006) Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther 8: R105.

67. Batliwalla FM, Baechler EC, Xiao X, Li W, Balasubramanian S, et al. (2005) Peripheral blood gene expression profiling in rheumatoid arthritis. Genes Immun 6: 388-397.

68. Emamian ES, Leon JM, Lessard CJ, Grandits M, Baechler EC, et al. (2009) Peripheral blood gene expression profiling in Sjögren's syndrome. Genes Immun 10: 285-296.

69. Kaizer EC, Glaser CL, Chaussabel D, Banchereau J, Pascual V, et al. (2007) Gene expression in peripheral blood mononuclear cells from children with diabetes. J Clin Endocrinol Metab 92: 3705-3711.

70. Takamura T, Honda M, Sakai Y, Ando H, Shimizu A, et al. (2007) Gene expression profiles in peripheral blood mononuclear cells reflect the pathophysiology of type 2 diabetes. Biochem Biophys Res Commun 361: 379-384.

71. Burczynski ME, Peterson RL, Twine NC, Zuberek KA, Brodeur BJ, et al. (2006) Molecular classification of Crohn's disease and ulcerative colitis patients using transcriptional profiles in peripheral blood mononuclear cells. J Mol Diagn. 8: 51-61.

72. Bhargava V, Ko P, Willems E, Mercola M, Subramaniam S (2013) Quantitative transcriptomics using designed primer-based amplification. Sci Rep 3: 1740.

73. Heidecker B, Kittleson MM, Kasper EK, Wittstein IS, Champion HC, et al. (2011) Transcriptomic biomarkers for the accurate diagnosis of myocarditis. Circulation 123: 1174-1184.

74. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, et al. (2008) Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 26: 317-325.

75. Chaussabel D, Pascual V, Banchereau J (2010) Assessing the human immune system through blood transcriptomics. BMC Biol 8: 84.

76. Baranzini SE (2009) The genetics of autoimmune diseases: a networked perspective. Curr Opin Immunol 21: 596-605.

77. Sánchez-Pla A, Reverter F, Ruíz de Villa MC, Comabella M (2012) Transcriptomics: mRNA and alternative splicing. J Neuroimmunol 248: 23-31.

78. Eberwinea J, Bartfaic T (2011) Single cell transcriptomics of hypothalamic warm sensitive neurons that control core body temperature and fever response: Signaling asymmetry and an extension of chemical neuroanatomy. Pharmacology and Therapeutics 129: 241-259.

79. Satpathy AT, Wu X, Albring JC, Murphy KM (2012) Re(de)fining the dendritic cell lineage. Nat Immunol 13: 1145-1154.

80. Miller JC, Brown BD, Shay T, Gautier EL, Jojic V (2012) Immunological Genome Consortium. Deciphering the transcriptional network of the dendritic cell lineage. Nat. Immunol 13: 888-899.

81. Shalek AK, Satija R, Adiconis X, Gertner RS, Gaublomme JT, et al. (2013) Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells. Nature 498: 236-240.

82. Gupta B, Iancu EM, Gannon PO, Wieckowski S, Baitsch L, et al. (2012) Simultaneous coexpression of memory-related and effector-related genes by individual human CD8 T cells depends on antigen specificity and differentiation. J Immunother 35: 488-501.

83. Iancu EM, Gannon PO, Laurent J, Gupta B, Romero P, et al. (2013) Persistence of EBV antigen-specific CD8 T cell clonotypes during homeostatic immune reconstitution in cancer patients. PLoS One 8.

84. Snijder B, Sacher R, Rämö P, Damm EM, Liberali P, et al. (2009) Population context determines cell-to-cell variability in endocytosis and virus infection. Nature 461: 520-523.

85. Snijder B, Pelkmans L (2011) Origins of regulated cell-to-cell variability. Nat Rev Mol Cell Biol 12: 119-125.

86. Takeichi M (1991) Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251: 1451-1455.

87. Herderschee J, Fenwick C, Pantaleo G, Roger T, Calandra T (2015) Emerging single-cell technologies in immunology. J Leukoc Biol 98: 23-32.

88. Jaitin DA, Kenigsberg E, Keren-Shaul H, Elefant N, Paul F, et al. (2014) Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types. Science 343: 776-779.

89. Choy E (2012) Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 51 Suppl 5: 3-11.
90. Silverman ED, Isacovics B, Petsche D, Laxer RM (1993) Synovial fluid cells in juvenile arthritis: evidence of selective T cell migration to inflamed tissue. Clin Exp Immunol 91: 90-95.
91. Covey TM, Cesano A, Parkinson DR (2010) Single-cell network profiling (SCNP) by flow cytometry in autoimmune disease. Autoimmunity 43: 550-559.
92. Snijder B, Sacher R, Rämö P, Liberali P, Mench K, et al. (2012) Single-cell analysis of population context advances RNAi screening at multiple levels. Molecular Systems Biology 8: 579.
93. Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, et al. (2005) Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64: 913-920.
94. Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, et al. (2007) Autoimmune diseases induced by TNF- targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86: 242-251.
95. Morris J, Singh JM, Eberwine JH (2011) Transcriptome Analysis of Single Cells. J Vis Exp 25.
96. Smeenk RJT (2000) Antinuclear antibodies: cause of disease or caused by disease? Rheumatology, 39: 581-584.
97. Geigl JB, Speicher MR (2007) Single-cell isolation from cell suspensions and whole genome amplification from single cells to provide templates for CGH analysis. Nat Protoc 2: 3173-3184.
98. Bontoux N, Dauphinot L, Vitalis T, Studer V, Chen Y, et al. (2008) Integrating whole transcriptome assays on a lab-on-a-chip for single cell gene profiling. Lab Chip 8: 443-450.
99. Irimia D, Tompkins RG, Toner M (2004) Single-cell chemical lysis in picoliter-scale closed volumes using a microfabricated device. Anal Chem 76: 6137-6143.
100. Marcus JS, Anderson WF, Quake SR (2006) Microfluidic single-cell mRNA isolation and analysis. Anal Chem 78: 3084-3089.
101. Mittal N, Rosenthal A, Voldman J (2007) nDEP microwells for single-cell patterning in physiological media. Lab Chip 7: 1146-1153.
102. Sedgwick H, Caron F, Monaghan PB, Kolch W, Cooper JM (2008) Lab-on-a-chip technologies for proteomic analysis from isolated cells. J R Soc Interface 5 Suppl 2: S123-S130.
103. Aaron MS, Xiannian Z, Chen C, Yuhong P, Xinglong W, et al. (2014) Microfluidic single-cell whole-transcriptome sequencing. PNAS 111: 7048-7053.
104. Islam S, Kjallquist U, Moliner A, Zajac P, Fan JB, et al. (2011) Characterization of the single-cell transcriptional landscape by highly multiplex RNA-seq. Genome Res 21: 1160-1167.
105. Ramsköld D, Luo S, Wang YC, Li R, Deng Q, et al. (2012) Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells. Nat Biotechnol 30: 777-782.
106. Islam S, Kjällquist U, Moliner A, Zajac P, Fan JB, et al. (2012) Highly multiplexed and strand-specific single-cell RNA 5' end sequencing. Nat Protoc 7: 813-828.
107. Hashimshony T, Wagner F, Sher N, Yanai I (2012) CEL-Seq: single-cell RNA-Seq by multiplexed linear amplification. Cell Rep 2: 666-673.
108. Tang F, Barbacioru C, Wang Y, Nordman E, Lee C, et al. (2009) mRNA-Seq whole-transcriptome analysis of a single cell. Nat Methods 6: 377-382.
109. Tang F, Barbacioru C, Nordman E, Li B, Xu N, et al. (2010) RNA-Seq analysis to capture the transcriptome landscape of a single cell. Nat Protoc 5: 516-535.
110. Kohn AB, Moroz TP, Barnes JP, Netherton M, Moroz LL (2013) Single-cell semiconductor sequencing. Methods Mol Biol 1048: 247-284.
111. Pan X, Durrett RE, Zhu H, Tanaka Y, Li Y, et al. (2013) Two methods for full-length RNA sequencing for low quantities of cells and single cells. Proc Natl Acad Sci USA 110: 594-599.
112. Picelli S, Björklund ÅK, Faridani OR, Sagasser S, Winberg G, et al. (2013) Smart-seq2 for sensitive full-length transcriptome profiling in single cells. Nat Methods 10: 1096-1098.
113. Sasagawa Y, Nikaido I, Hayashi T, Danno H, Uno KD, et al. (2013) Quartz-Seq: a highly reproducible and sensitive single-cell RNA sequencing method, reveals non-genetic gene-expression heterogeneity. Genome Biol 14: R31.
114. Soumillon M, Cacchiarelli D, Semrau S, Oudenaarden A van, Mikkelsen TS (2014) Characterization of directed differentiation by high-throughput single-cell RNA-Seq.
115. Jiang L, Schlesinger F, Davis CA, Zhang Y, Li R, et al. (2011) Synthetic spike-in standards for RNA-seq experiments. Genome Res 21: 1543-1551.
116. Kivioja T, Vähärautio A, Karlsson K, Bonke M, Enge M, et al. (2011) Counting absolute numbers of molecules using unique molecular identifiers. Nat Methods 9: 72-74.
117. Ozsolak F, Milos PM (2011) Single-molecule direct RNA sequencing without cDNA synthesis. Wiley Interdiscip Rev RNA 2: 565-570.
118. Coupland P, Chandra T, Quail M, Reik W, Swerdlow H (2012) Direct sequencing of small genomes on the Pacific Biosciences RS without library preparation. Biotechniques 53: 365-372.
119. Fessenden M (2015) Pushing the Limits: A guide to the newest techniques for examining epigenetics in single cells. The Scientist 29.